Login Register Cart 0
Generic placeholder image

Current Neurovascular Research

Editor-in-Chief

ISSN (Print): 1567-2026
ISSN (Online): 1875-5739

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Intravenous Thrombolysis is Effective in Mild Stroke Patients with an Admission NIHSS Score of 3 to 5

Author(s): Kai Zhang and Lin Han*

Volume 20, Issue 4, 2023

Published on: 31 October, 2023

Page: [434 - 442] Pages: 9

DOI: 10.2174/0115672026275063231023110030

Price: $65

Abstract

Background and Purpose: The role of intravenous thrombolysis in patients with acute mild ischemic stroke remains highly controversial. Therefore, this study aims to analyze the efficacy and safety of intravenous thrombolysis in patients with mild ischemic stroke based on admission National Institutes of Health Stroke Scale (NIHSS) score.

Methods: The present study enrolled 507 patients with acute mild ischemic stroke admitted within 4.5 hours of symptom onset with an admission NIHSS score of 0 to 5. Patients were assigned to two groups based on admission NIHSS scores of 0 to 2 and 3 to 5, and subsequent analyses compared functional outcomes between thrombotic and non-thrombotic patients within these groups. The primary outcome was a modified Rankin score (mRS) of 0 or 1 at 90 days, representing functional independence. The safety outcomes were symptomatic intracranial hemorrhage (sICH), early neurological deterioration (END), and the rate of stroke recurrence within 90 days.

Results: Among the 267 patients with NIHSS scores of 0 to 2, 112 (41.9%) patients received intravenous thrombolysis. Overall, thrombolysis administration did not significantly improve the patient's functional prognoses at 90 days (adjusted OR=1.046, 95%CI=0.587-1.863, p = 0.878). However, there was a marked increase in the risk of sICH (p = 0.030). Of the 240 patients with NIHSS scores of 3 to 5, 155 (64.6%) patients received intravenous thrombolysis, resulting in a significant improvement in 90-day functional prognosis (adjusted OR=3.284, 95%CI=1.876- 5.749, p < 0.001) compared to those that did not receive thrombolysis intervention. Importantly, there was no significant increase in sICH incidence (adjusted OR=2.770, 95%CI=0.313-24.51, p = 0.360). There were no statistically significant differences in END or the rate of stroke recurrence within 90 days between thrombotic and non-thrombotic groups.

Conclusions: Intravenous thrombolysis is safe and effective in patients with baseline NIHSS scores of 3 to 5. In contrast, it did not improve 90-day functional outcomes in patients with NIHSS scores of 0 to 2 and instead increased the risk of sICH.

« Previous Next »
[1]
Wang Y, Li Z, Wang Y. et al. Chinese Stroke Center Alliance: A national effort to improve healthcare quality for acute stroke and transient ischaemic attack: Rationale, design and preliminary findings. Stroke Vasc Neurol 2018; 3(4): 256-62.
[http://dx.doi.org/10.1136/svn-2018-000154] [PMID: 30637133]
[2]
Fischer U, Baumgartner A, Arnold M. et al. What is a minor stroke? Stroke 2010; 41(4): 661-6.
[http://dx.doi.org/10.1161/STROKEAHA.109.572883] [PMID: 20185781]
[3]
Wang YL, Wu D, Liao X, Zhang W, Zhao X, Wang YJ. Burden of stroke in China. Int J Stroke 2007; 2(3): 211-3.
[http://dx.doi.org/10.1111/j.1747-4949.2007.00142.x] [PMID: 18705946]
[4]
Wang Y, Wang Y, Zhao X. et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013; 369(1): 11-9.
[http://dx.doi.org/10.1056/NEJMoa1215340] [PMID: 23803136]
[5]
Johnston SC, Easton JD, Farrant M. et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med 2018; 379(3): 215-25.
[http://dx.doi.org/10.1056/NEJMoa1800410] [PMID: 29766750]
[6]
Pan Y, Elm JJ, Li H. et al. Outcomes associated with clopidogrel-aspirin use in minor stroke or transient ischemic attack. JAMA Neurol 2019; 76(12): 1466-73.
[http://dx.doi.org/10.1001/jamaneurol.2019.2531] [PMID: 31424481]
[7]
Marko M, Posekany A, Szabo S. et al. Trends of r-tPA (recombinant tissue-type plasminogen activator) treatment and treatment-influencing factors in acute ischemic stroke. Stroke 2020; 51(4): 1240-7.
[http://dx.doi.org/10.1161/STROKEAHA.119.027921] [PMID: 32114931]
[8]
Wang X, Li X, Xu Y. et al. Effectiveness of intravenous r-tPA versus UK for acute ischaemic stroke: A nationwide prospective Chinese registry study. Stroke Vasc Neurol 2021; 6(4): 603-9.
[http://dx.doi.org/10.1136/svn-2020-000640] [PMID: 33903179]
[9]
Romano JG, Smith EE, Liang L. et al. Outcomes in mild acute ischemic stroke treated with intravenous thrombolysis: A retrospective analysis of the Get With the Guidelines-Stroke registry. JAMA Neurol 2015; 72(4): 423-31.
[http://dx.doi.org/10.1001/jamaneurol.2014.4354] [PMID: 25642650]
[10]
Khatri P, Kleindorfer DO, Devlin T. et al. Effect of alteplase vs aspirin on functional outcome for patients with acute ischemic stroke and minor nondisabling neurologic deficits. JAMA 2018; 320(2): 156-66.
[http://dx.doi.org/10.1001/jama.2018.8496] [PMID: 29998337]
[11]
Powers WJ, Rabinstein AA, Ackerson T. et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: A guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2019; 50(12): e344-418.
[http://dx.doi.org/10.1161/STR.0000000000000211] [PMID: 31662037]
[12]
Berge E, Whiteley W, Audebert H. et al. European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke. Eur Stroke J 2021; 6(1): I-LXII.
[http://dx.doi.org/10.1177/2396987321989865] [PMID: 33817340]
[13]
Romano JG, Gardener H, Campo-Bustillo I. et al. Predictors of outcomes in patients with mild ischemic stroke symptoms: MaRISS. Stroke 2021; 52(6): 1995-2004.
[http://dx.doi.org/10.1161/STROKEAHA.120.032809] [PMID: 33947209]
[14]
Sykora M, Krebs S, Simader F. et al. Intravenous thrombolysis in stroke with admission NIHSS score 0 or 1. Int J Stroke 2022; 17(1): 109-19.
[http://dx.doi.org/10.1177/1747493021991969] [PMID: 33568019]
[15]
Choi JC, Kim BJ, Han MK. et al. Utility of items of baseline national institutes of health stroke scale as predictors of functional outcomes at three months after mild ischemic stroke. J Stroke Cerebrovasc Dis 2017; 26(6): 1306-13.
[http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2017.01.027] [PMID: 28318959]
[16]
Adams HP Jr, Bendixen BH, Kappelle LJ. et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24(1): 35-41.
[http://dx.doi.org/10.1161/01.STR.24.1.35] [PMID: 7678184]
[17]
Hacke W, Kaste M, Fieschi C. et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998; 352(9136): 1245-51.
[http://dx.doi.org/10.1016/S0140-6736(98)08020-9] [PMID: 9788453]
[18]
Tu WJ, Xu Y, Liu Y, Li J, Du J, Zhao J. Intravenous thrombolysis or medical management for minor strokes. Thromb Haemost 2023; 123(7): 734-43.
[http://dx.doi.org/10.1055/s-0043-1768150] [PMID: 37037201]
[19]
Wang L, Li G, Hao Y, Hao M, Xiong Y. Intravenous thrombolysis for mild stroke: NIHSS 3-5 versus NIHSS 0–2. J Stroke Cerebrovasc Dis 2023; 32(5): 107070.
[http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2023.107070] [PMID: 36905743]
[20]
National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. National Institute of Neurological D and Stroke rt PASSG Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333(24): 1581-8.
[http://dx.doi.org/10.1056/NEJM199512143332401]
[21]
Heldner MR, Jung S, Zubler C. et al. Outcome of patients with occlusions of the internal carotid artery or the main stem of the middle cerebral artery with NIHSS score of less than 5: Comparison between thrombolysed and non-thrombolysed patients. J Neurol Neurosurg Psychiatry 2015; 86(7): 755-60.
[http://dx.doi.org/10.1136/jnnp-2014-308401] [PMID: 25266203]
[22]
Wang D, Zhang L, Hu X. et al. Intravenous thrombolysis benefits mild stroke patients with large-artery atherosclerosis but no tandem stenoocclusion. Front Neurol 2020; 11: 340.
[http://dx.doi.org/10.3389/fneur.2020.00340] [PMID: 32431662]
[23]
Haeberlin MI, Held U, Baumgartner RW, Georgiadis D, Valko PO. Impact of intravenous thrombolysis on functional outcome in patients with mild ischemic stroke without large vessel occlusion or rapidly improving symptoms. Int J Stroke 2020; 15(4): 429-37.
[http://dx.doi.org/10.1177/1747493019874719] [PMID: 31514684]
[24]
You S, Saxena A, Wang X. et al. Efficacy and safety of intravenous recombinant tissue plasminogen activator in mild ischaemic stroke: A meta-analysis. Stroke Vasc Neurol 2018; 3(1): 22-7.
[http://dx.doi.org/10.1136/svn-2017-000106] [PMID: 29600004]
[25]
Köhrmann M, Nowe T, Huttner HB. et al. Safety and outcome after thrombolysis in stroke patients with mild symptoms. Cerebrovasc Dis 2009; 27(2): 160-6.
[http://dx.doi.org/10.1159/000185607] [PMID: 19092237]
[26]
Huisa BN, Raman R, Neil W, Ernstrom K, Hemmen TM. Intravenous tissue plasminogen activator for patients with minor ischemic stroke. J Stroke Cerebrovasc Dis 2012; 21(8): 732-6.
[http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2011.03.009] [PMID: 21531576]
[27]
Hacke W, Kaste M, Bluhmki E. et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359(13): 1317-29.
[http://dx.doi.org/10.1056/NEJMoa0804656] [PMID: 18815396]
[28]
Wardlaw JM, Murray V, Berge E. et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: An updated systematic review and meta-analysis. Lancet 2012; 379(9834): 2364-72.
[http://dx.doi.org/10.1016/S0140-6736(12)60738-7] [PMID: 22632907]
[29]
Mundiyanapurath S, Hees K, Ahmed N. et al. Predictors of symptomatic intracranial haemorrhage in off‐label thrombolysis: An analysis of the Safe Implementation of Treatments in Stroke registry. Eur J Neurol 2018; 25(2): 340-e11.
[http://dx.doi.org/10.1111/ene.13507] [PMID: 29105904]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy